ahlam1399
03-23-2016, 03:51 AM
Merck patents on Hepatitis C treatment found valid in Gilead dispute
SAN JOSE (Reuters) - A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e726756/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=l913Xn7hWmw:8W6L9526e7M:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=l913Xn7hWmw:8W6L9526e7M:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=l913Xn7hWmw:8W6L9526e7M:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=l913Xn7hWmw:8W6L9526e7M:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=l913Xn7hWmw:8W6L9526e7M:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/l913Xn7hWmw
SAN JOSE (Reuters) - A federal jury on Tuesday upheld the validity of two Merck & Co patents in a high-profile dispute with rival Gilead Sciences Inc, which could be forced to hand over a portion of the billions of dollars in revenue from its blockbuster cure for hepatitis C.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4e726756/sc/28/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=l913Xn7hWmw:8W6L9526e7M:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=l913Xn7hWmw:8W6L9526e7M:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=l913Xn7hWmw:8W6L9526e7M:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=l913Xn7hWmw:8W6L9526e7M:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=l913Xn7hWmw:8W6L9526e7M:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/l913Xn7hWmw